Intuitive Surgical’s Stock Jumps As Demand for Robotic Procedures Rises

Key Takeaways

Intuitive Surgical, maker of the da Vinci and Ion systems, beat third-quarter profit and sales forecasts. That lifted the shares into the plus column for 2025.
The company is “in the driver’s seat” of its market, William Blair analysts wrote.

Intuitive Surgical (ISRG) shares jumped Wednesday after the maker of robotic surgical devices posted much better-than-expected quarterly results and raised its guidance on increased use of its units.

The maker of the da Vinci and Ion systems reported third-quarter adjusted earnings per share of $2.40, $0.42 more than analysts surveyed by Visible Alpha expected. Revenue increased 23% to $2.51 billion, also above estimates.

Intuitive sees full-year da Vinci procedure growth of 17% to 17.5%, better than its previous outlook of 15.5% to 17.0%, and gross profit margin of 67.0% to 67.5% versus an earlier prediction of 66.0% to 67.0%.

The news lifted the shares, with the stock recently up more than 14%—and back in the green for the year for the first time in months.

Why This Is Significant

Intuitive Surgical’s strong quarterly results signal robust demand for robotics and its expanding applications in health care. With procedure volumes climbing worldwide and system placements increasing, the company is benefiting from broader adoption of minimally invasive surgery technology—and its stock is back in the green for 2025.

The company said the revenue gains were driven by “growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of systems.”

Intuitive “remains in the driver’s seat of a market converting to robotics,” analysts at William Blair wrote. They have an “outperform” rating on the shares.

Worldwide procedures using da Vinci minimally invasive surgical devices increased 19%, while those using the Ion systems increased 52%. Placements of the da Vinci rose 13%, while Ion systems’ placements declined 14%.

Source link